The American Journal of Medicine · Jun 30, 2026
GLP-1 receptor agonists and age-related macular degeneration risk in diabetes or non-diabetic obesity: A retrospective cohort study
By Pan SY, Weng CH, Sheen YJ et al.
OBJECTIVE: We conducted a retrospective cohort study to examine the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and age-related macular degeneration. METHODS: This is a retrospective cohort study including two cohorts of adults aged ≥50 years free of macular degeneration at baseline, including 1) the diabetes cohort comparing age-related macular degeneration risk between GLP-1RAs and metformin users, and 2) the obesity cohort, consisting of individuals with a body mass index ≥30 kg/m² without type 2 diabetes, comparing the risk of age-related macular degeneration between GLP-1RAs and other weight-loss medications. A 1:1 propensity score matching was performed to balance covariates. Cox proportional hazards models and Kaplan-Meier analysis were used to assess the risk of age-related macular degeneration across 5 years of follow-up. RESULTS: A total of 147,800 participants with diabetes and 49,518 participants with obesity were included. In the diabetes cohort, GLP-1RAs were associated with lower total age-related macular degeneration (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.75-0.91) and dry age-related macular degeneration (HR, 0.84; 95% CI, 0.73-0.98) risks compared to metformin. In the obesity cohort, GLP-1RAs were associated with a lower risk of total age-related macular degeneration (HR, 0.77; 95% CI, 0.61-0.98) and dry age-related macular degeneration (HR, 0.65; 95% CI, 0.46-0.94) compared to other weight-loss medications. CONCLUSIONS: GLP-1RAs were associated with a lower risk of age-related macular degeneration, particularly the dry form, compared with metformin or other weight-loss medications.
doi.org/10.1016/j.amjmed.2026.06.023PubMed 42379510Populations